Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination)

Techniker Krankenkasse · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

November 30, 2026
Response Due
Active
Status

Opportunity Overview

Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Emtricitabin/Tenofovirdisoproxil/Rilpivirin zu schließen.

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyTechniker Krankenkasse
CountryGermany
CategoryPharmaceuticals
PublishedAugust 14, 2026
Procurement stageRequest for Proposal (RFP)
Response dueNovember 30, 2026
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Dapagliflozin, ATC A10BK01 für die Zeit 01.10.2026 - 30.09.2028
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Follitropin alfa (ATC: G03GA05)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Silodosin, ATC G04CA04
Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)
Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-10
Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-15
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.